Furthermore, the demonstration of cardiovascular benefits across a broad range of adiposity levels, coupled with independence from weight loss magnitude, suggests that semaglutide and perhaps other GLP-1 receptor agonists should be reconceptualized as cardiovascular disease-modifying agents rather than solely medications for glycemic control or weight loss
Women in menopause taking both semaglutide and hormone replacement therapy (HRT) lost 16 percent of their body weight (a statistically significant difference)
Passive Caloric Restriction Semaglutide: The Classic Single Receptor Agonist Semaglutide mimics only one natural incretin hormone in the body: GLP-1 (Glucagon-like peptide-1)
We serve communities across the region, including St Helens (Garswood, Heatons, Millfields, Haydock, and Bradlegh), Wigan (Moorside, Mesnes, Ince, and Blackhorse/Blackrod), Bolton (Market), Trafford (Sale and Village), Northwich (Barnton), Crewe, and Clayton in Staffordshire